OTC · KLYG
Healthcare · Medical - Devices
$0.14
Up+$0.02 (+16.67%)
Updated Oct 10, 2026, 2:44 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · KLYG
1M range · 7 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
KLYG closed at $0.14 after 7 trading sessions, up 19.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $0.12 | $0.1399 | $0.12 | $0.1399 | 11.32K |
| Oct 6, 2026 | $0.12 | $0.12 | $0.12 | $0.12 | 3.71K |
| Oct 5, 2026 | $0.12 | $0.12 | $0.12 | $0.12 | 3.26K |
| Oct 1, 2026 | $0.1301 | $0.1301 | $0.1301 | $0.1301 | 5.05K |
| Sep 28, 2026 | $0.139 | $0.139 | $0.139 | $0.139 | 4.4K |
| Sep 17, 2026 | $0.1169 | $0.1188 | $0.1169 | $0.1188 | 2.22K |
| Sep 15, 2026 | $0.121 | $0.1229 | $0.1169 | $0.1169 | 28.47K |
The latest Smart Investors Daily articles mentioning KLYG.
Company
Market Activity
Research & News
KLYG research
Company profile and research snapshot.
KELYNIAM GLOBAL INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · May 11, 2026
Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today reported its financial results for the first quarter ended March 31, 2026. The company delivered excellent performance, with strong revenue growth and clear improvement in profitability.
GlobeNewswire Inc. · Nov 13, 2025
Kelyniam Global has obtained an exclusive two-year U.S. license from Evonik Industries to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial and craniofacial implants, expanding its regenerative medicine portfolio.
Yahoo · Nov 13, 2025
CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial, craniofacial, and maxillofacial implants. This agreement grants Kelyniam two years of exclusivity with the option for renewal upon mutual agreement. The license enhances Kelyniam's regenerati
Benzinga · Nov 10, 2025
Kelyniam Global reported Q3 2025 financial results with decreased revenue and an operating loss, but remains optimistic about growth in the cranial implant sector through new product clearances and distributor expansion.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KLYG.
No results
No recent SID articles mention KLYG.
